Accès ouvert déclaré 2024 article

Monoclonal antibodies against SARS-CoV-2 to prevent COVID-19 worsening in a large multicenter cohort

Alessandro Soria, Francesca Graziano, Giulia Irene Ghilardi, Giuseppe Lapadula, Daniela Dalla Gasperina, Simone Vasilij Benatti, Eugenia Quirós-Roldán, Maurizio Milesi, Francesca Bai, Marco Merli, Davide Minisci, Marco Franzetti, Erika Asperges, Filippo Chiabrando, Daria Pocaterra, Alessandro Pandolfo, Fabio Zanini, Doménico Lombardi, Anna Cappelletti, Alban Rugova, Maria Lucia Borghesi, Nicola Squillace, Luigi Pusterla, Stefania Piconi, Paola Morelli, Patrizia Rovere‐Querini, Raffaele Bruno, Stefano Rusconi, Salvatore Casari, Alessandra Bandera, Fabio Franzetti, Giovanna Travi, Antonella D'Arminio Monforte, Giulia Marchetti, Angelo Pan, Francesco Castelli, Marco Rizzi, Francesco Dentali, M Mallardo, Emanuela Rossi, Maria Grazia Valsecchi, Stefania Galimberti, Paolo Bonfanti

1Citations signalées, ce qui n’est pas une note de qualité

25Institutions déclarées

2Pays d’affiliation déclarés

Rattachement africain : it, us. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Abstract Objective Monoclonal antibodies (mAbs) against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) reduced Coronavirus Disease 2019 (COVID-19) hospitalizations in people at risk of clinical worsening. Real-world descriptions are limited. Methods CONDIVIDIAMO, a two-year multicenter observational study, consecutively enrolled SARS-CoV-2 outpatients with ≥1 risk factor for COVID-19 progression receiving mAbs. Demographic data, underlying medical condition, type of mAbs combination received, duration of symptoms before mAbs administration, COVID-19 vaccination history, were collected upon enrolment and centrally recorded. Data on outcomes (hospitalizations, reasons of hospitalization, deaths) were prospectively collected. The primary endpoint was the rate of hospitalization or death in a 28-day follow-up, whichever occurred first; subjects were censored at the day of last follow-up or up to 28 days. The Kaplan-Meier method was used to estimate the incidence rate curve in time. The Cox regression model was used to assess potential risk factors for unfavorable outcome. Results were shown as hazard ratio (HR) along with the corresponding 95 % Confidence Interval (95%CI). Results Among 1534 subjects (median [interquartile range, IQR] age 66.5 [52.4–74.9] years, 693 [45.2 %] women), 632 (41.2 %) received bamlanivimab ± etesevimab, 209 (13.6 %) casirivimab/imdevimab, 586 (38.2 %) sotrovimab, 107 (7.0 %) tixagevimab/cilgavimab. After 28-day follow-up, 87/1534 (5.6 %, 95%CI: 4.4%–6.8 %) met the primary outcome (85 hospitalizations, 2 deaths). Hospitalizations for COVID-19 (52, 3.4 %) occurred earlier than for other reasons (33, 2.1 %), after a median (IQR) of 3.5 (1–7) versus 8 (3–15) days (p = 0.006) from mAbs administration. In a multivariable Cox regression model, factors independently associated with increased hospitalization risk were age (hazard ratio [HR] 1.02, 95%CI 1.00–1.03, p = 0.021), immunodeficiency (HR 1.78, 95%CI 1.11–2.85, p = 0.017), pre-Omicron calendar period (HR 1.66, 95%CI 1.02–2.69, p = 0.041). Conclusions MAbs real-world data over a 2-year changing pandemic landscape showed the feasibility of the intervention, although the hospitalization rate was not negligible. Immunosuppressed subjects remain more at risk of clinical worsening.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref: Monoclonal antibodies against SARS-CoV-2 to prevent COVID-19 worsening in a large multicenter cohort
Date Crossref: 01/08/2024
Éditeur: Elsevier BV
Type: journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Où se fait cette recherche

Azienda Ospedaliera San Gerardo pays non établi dans la notice
Établissement de santé
Istituti di Ricovero e Cura a Carattere Scientifico pays non établi dans la notice
Établissement de santé
University of Milano-Bicocca Department of Health Sciences pays non établi dans la notice
Université ou école supérieure
University of Insubria Department of Medicine and Technological Innovation pays non établi dans la notice
Université ou école supérieure
American Association for the Surgery of Trauma pays non établi dans la notice
Organisation à but non lucratif
AOL (United States) pays non établi dans la notice
Entreprise
Ospedale Papa Giovanni XXIII pays non établi dans la notice
Établissement de santé
University of Brescia Clinic of Infectious Diseases pays non établi dans la notice
Université ou école supérieure
Istituti Ospitalieri di Cremona pays non établi dans la notice
Établissement de santé
University of Milan pays non établi dans la notice
Université ou école supérieure
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda pays non établi dans la notice
Établissement de santé
Music Conservatory of Mantova pays non établi dans la notice
Université ou école supérieure

Azienda Ospedaliera San Gerardo, Istituti di Ricovero e Cura a Carattere Scientifico et Department of Health Sciences — University of Milano-Bicocca, avec 9 autres affiliations.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesImmune responses and vaccinations

Lire en accès ouvert Consulter la publication primaire Ouvrir le DOI